Car T-Cell Therapy
FDA accepts IND for allogenic CAR T-cell therapy that could bypass lymphodepletion
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases.
VIDEO: New immunotherapies developing for multiple myeloma
In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.
VIDEO: New drug classes for multiple myeloma treatment
In this video, Sham Mailankody, MBBS discusses the latest in the study and treatment of multiple myeloma.
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor
A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets the immune checkpoint B7-H3 for diffuse intrinsic pontine glioma, or DIPG, a rare incurable pediatric brain tumor.
CAR T therapy for autoimmune disease exploded in 2024. Here’s what you may have missed
After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor T-cell therapies for autoimmune rheumatic diseases.
VIDEO: Keto diet may improve CAR T-cell therapy antitumor function, early research shows
SAN DIEGO — A ketogenic diet may improve antitumor function through beta-hydroxybutyrate, according to early research presented in a plenary scientific session at the ASH Annual Meeting and Exposition.
VIDEO: CAR T-cell therapy made in 1 day had good safety, efficacy in phase 1 trial
SAN DIEGO — A new chimeric antigen receptor T-cell therapy option made in less than a day may be a new option for patients with relapsed/refractory non-Hodgkin lymphoma, according to research presented at ASH Annual Meeting and Exposition.
CAR T therapy shows ‘no major hematotoxicites’ in autoimmune disease phase 1/2 study
WASHINGTON — A phase 1/2 study of CD19 chimeric antigen receptor T-cell therapy in lupus and other autoimmune diseases demonstrated significant response with minimal toxicities, according to data presented at ACR Convergence 2024.
VIDEO: Updates in CAR T-cell therapy from ASH 2024
SAN DIEGO — Paolo Caimi, MD, spoke with Healio about research updates on chimeric antigen receptor T-cell therapy presented at ASH Annual Meeting and Exposition.